Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Veliparib - Abbvie

Drug Profile

Veliparib - Abbvie

Alternative Names: ABT 888; NSC 737664

Latest Information Update: 28 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories; University of Alabama at Birmingham
  • Developer Abbott Laboratories; AbbVie; Georgetown University; Narodny onkologicky ustav; National Cancer Institute (USA); Northwestern University; University of Alabama at Birmingham
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Breast cancer; Non-small cell lung cancer; Ovarian cancer
  • Phase II/III Glioblastoma
  • Phase II Brain metastases; Colorectal cancer; Germ cell and embryonal neoplasms; Malignant melanoma; Pancreatic cancer; Rectal cancer; Solid tumours
  • Phase I/II Glioma; Head and neck cancer; Small cell lung cancer
  • Phase I Lymphoma
  • No development reported Multiple myeloma; Prostate cancer
  • Discontinued Liver cancer

Most Recent Events

  • 28 Nov 2019 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Combination therapy, Second-line therapy or greater) in Germany (IV, Infusion)
  • 15 Oct 2019 National Cancer Institute suspends a phase II trial in Rectal cancer (Neoadjuvant therapy, Late-stage disease, First-line therapy, Combination therapy) in USA and Puerto Rico (PO) (NCT02921256)
  • 02 Oct 2019 AbbVie completes a phase II trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA, Spain, Hungary and Czech Republic (PO, Capsule) (NCT02944396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top